GLP-1 Approved

🔬 Trial data vs real-world evidence: what’s the difference? Let’s take a GLP-1 medicine as an example. In a clinical trial: Researchers may study semaglutide in a carefully selected group of participants, following a defined dose schedule and monitoring outcomes under controlled conditions. In the real world: Researchers may examine health records to understand how people using semaglutide in everyday healthcare settings get on — including treatment persistence, dose changes, side effects and outcomes. Why does this matter? Someone may stop treatment early, miss doses or have their dose adjusted in routine care. These factors can influence real-world outcomes but may be handled differently in a controlled trial. Both types of evidence are valuable: Clinical trials help establish efficacy and assess safety under defined conditions. Real-world evidence helps us understand how findings translate into everyday healthcare. The key is knowing what each type of research can — and can't — tell us. #GLP1 #Semaglutide #HealthResearch #EvidenceBased

💊 Taking a prescribed GLP-1 medicine? Know your leaflet. Each medicine has its own instructions. The patient information leaflet explains how to use it, possible side effects and when to seek medical advice. Not sure what something means? Ask your prescriber or pharmacist rather than guessing. A few minutes reading can help you make more informed decisions about medicine safety. #GLP1 #MedicinesSafety

💬 What should we unpack next? GLP-1 research covers more than weight loss. Which topic would you like us to explore next? A. Heart health B. Kidney health C. Sleep apnoea D. Oral GLP-1 medicines E. Side effects F. Weight regain after stopping treatment 👇Reply with a letter or drop your own question in the comments! Let’s make GLP-1 research easier to understand, one question at a time. #GLP1 #GLP1Community #Obesity

🔬 Trial data vs real-world evidence: what’s the difference? Randomised controlled trials ask: Can a treatment work under controlled conditions? Real-world studies ask: How does it perform in everyday healthcare? Both are valuable. Trials help assess efficacy and safety; real-world evidence can reveal how outcomes vary across routine care. The key? Understand what each study can and can’t tell us. #GLP1 #HealthResearch #GLP1Facts

⚖️ The number on the scale is only one part of the picture. Depending on your health, GLP-1 treatment reviews may also consider: 📏 Waist circumference 🩺 Blood pressure 🩸 Blood glucose & cholesterol 💪 Strength & nutrition 📝 Side effects and how you feel Weight is one metric - not the whole story. Your clinician can help determine what’s relevant for you. #GLP1 #WeightManagement #MetabolicHealth

📋 Staying organised during GLP-1 treatment can be easier with one simple logbook. Track your doses, weight, how you’re feeling and side effects. Review your history, plan ahead and export a record to share with your prescriber. 🔒 Your entries stay in your browser. Try the free GLP-1 Approved Logbook 👇 glp1approved.com/logbook #GLP1 #Mounjaro #Wegovy

Protein doesn’t have to mean another shake. Eggs, yoghurt, beans, lentils, tofu and other everyday foods can all contribute to your intake. Looking for practical ideas while taking GLP-1 medication? Explore our free Protein Planner 🔗glp1approved.com/tools/prote… #GLP1 #Protein #Nutrition

💷 The price of GLP-1 treatment isn't always just the price of the pen. Delivery, pharmacy fees and changing doses can all affect what you spend over time. Our Cost Planner helps you compare estimated 3, 6 or 12-month costs across pharmacies and add your own quote for a clearer picture. Plan ahead, compare the numbers. 👇 glp1approved.com/tools/cost-… #GLP1 #Mounjaro #Wegovy

Eating less can make it harder to know how to fit enough protein into your day. Our free Protein Planner helps you explore a daily protein range, plan around smaller meals and discover everyday food ideas. Make your nutrition feel more manageable. glp1approved.com/tools/prote… #GLP1 #Nutrition

Weight management is only one part of the bigger picture. ❤️ For people living with obesity-related heart failure, improving everyday life matters too from walking a little farther to feeling less limited by symptoms. Semaglutide has shown encouraging benefits in these areas, expanding the conversation around GLP-1s and heart health. #GLP1 #Semaglutide #HeartHealth

GLP-1 research is moving beyond weight loss. 🩺 In the FLOW trial, semaglutide reduced the risk of major kidney outcomes by 24% in people with type 2 diabetes and chronic kidney disease. Benefits extended to cardiovascular and survival outcomes. An important finding in metabolic health research. 🔗 Research: doi.org/10.1056/NEJMoa240334… #GLP1 #KidneyHealth #Semaglutide

Weight loss may affect more than the number on the scale. In the STEP 9 trial, adults with obesity and knee osteoarthritis who received once-weekly semaglutide had greater reductions in body weight and knee pain than those receiving placebo over 68 weeks. 📉 Weight change: −13.7% vs −3.2% 🦵 WOMAC pain score: −41.7 vs −27.5 points The findings suggest that weight management may play an important role in improving symptoms associated with knee osteoarthritis. 🔬 Research: pubmed.ncbi.nlm.nih.gov/3947… #GLP1 #Semaglutide #Osteoarthritis #KneeOsteoarthritis #ObesityResearch

GLP-1/GIP research is moving beyond the scale. In SURMOUNT-OSA, tirzepatide reduced sleep-apnoea severity, body weight and hypoxic burden in adults with obesity and moderate-to-severe OSA. Another signal that these medicines may affect more than weight. Read full research here: pubmed.ncbi.nlm.nih.gov/3891… #GLP1 #Tirzepatide #SleepApnea

GLP-1s may not always mean injections. In the OASIS 4 trial, once-daily oral semaglutide 25 mg produced 13.6% mean weight loss at 64 weeks, vs 2.2% with placebo in adults with overweight or obesity without diabetes. GI side effects were more common with semaglutide. Research: nejm.org/doi/10.1056/NEJMoa2… #GLP1 #Semaglutide #ObesityResearch

Could semaglutide’s heart benefits depend on more than weight loss? A 2026 observational study of 12,519 users found cardiovascular outcomes tracked more closely with dose reached than weight lost. A clue, not proof of causation. nature.com/articles/s44325-0…

Real-world data can look different from clinical trials. A 2026 study of 44,025 people found lower average weight loss with semaglutide and tirzepatide than figures reported in clinical trials. Importantly, people with 1 year of continuous GLP-1 prescriptions experienced greater weight loss than the overall treatment groups. Persistence matters. 🔬 Research: onlinelibrary.wiley.com/doi/… #GLP1 #Semaglutide #Tirzepatide #Obesity #RealWorldData

Not a “super responder”? That can still be normal. In SURMOUNT-5, 32% lost ≥15% by week 24. The other 68% lost <15% by then, and continued to lose weight through week 72. Progress can have different timelines. Study: pubmed.ncbi.nlm.nih.gov/4186… #GLP1 #WeightLoss

GLP-1 weight loss isn’t all fat loss. A 2026 meta-analysis of 7 trials found lean mass also fell, even as body composition improved. Protein, resistance training and nutrition matter. Study: nature.com/articles/s41366-0… #GLP1 #MuscleHealth #WeightLoss